SCHEMBL8025439

SCHEMBL8025439

COC(=O)c1cc(OCc2ccccc2)c(OC)cc1-c1noc(C(C)(C)C)n1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 2/20 0.45
HDAC1 Q13547 3/20 0.45
HDAC6 Q9UBN7 3/20 0.45
HDAC5 Q9UQL6 2/20 0.45
HDAC8 Q9BY41 2/20 0.43
HPGD P15428 3/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SRD5A1 P18405 2/20 0.41
SRD5A2 P31213 2/20 0.41
CTSV O60911 2/20 0.41
CTSL P07711 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CNR2 P34972 2/20 0.40
LMNA P02545 1/20 0.40
CNR1 P21554 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1617879 0.87 SMPD1 (0.47) SMPD1HDAC1HDAC6HDAC8HPGD
SCHEMBL8041185 0.85 POLB (0.47) SMPD1HDAC1HDAC6HDAC8HPGD
SCHEMBL8041191 0.83 SMPD1 (0.44) SMPD1HDAC1HDAC6HDAC8HPGD
SCHEMBL8025392 0.83 CNR2 (0.43) SMPD1HDAC1HDAC6HDAC5HDAC8
SCHEMBL8039671 0.83 HDAC6 (0.53) SMPD1HDAC1HDAC6HDAC5HDAC8
SCHEMBL12717270 0.80 SMPD1 (0.44) SMPD1HDAC1HDAC6HDAC8HPGD
SCHEMBL1617764 0.80 HTT (0.46) SMPD1HDAC1HDAC6HDAC8HPGD
SCHEMBL12717325 0.79 SMPD1 (0.46) SMPD1HDAC1HDAC6HDAC8HPGD
SCHEMBL8027539 0.79 MAPT (0.39) HPGDNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL1618359 0.79 SMPD1 (0.48) SMPD1HDAC1HDAC6HDAC8HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7923462-B2 Catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-04-12 US disclosed
US-7923462-B2 Catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-04-12 US disclosed
US-20100280083-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-11-04 US disclosed
US-20100280083-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-11-04 US disclosed
EP-2246338-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION Kissei Pharmaceutical Co., Ltd. (JP) 2010-11-03 EP disclosed
WO-2009081891-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280083-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION COMT, CYP2D6, CYP3A43 SMPD1 2029/4885HDAC1 2130/4885HDAC6 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.